Skip to main content
SpringerLink
Log in

Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

The pharmacokinetics of doxorubicin (DOX) encapsulated in liposomes containing polyethylene glycol-derivatized distearoylphosphatidylethanolamine (PEG/DSPE) were investigated in rodents and dogs. The plasma levels of DOX obtained with PEG/DSPE-containing liposomes were consistently higher than those without PEG/DSPE or when PEG/DSPE was replaced with hydrogenated phosphatidylinositol (HPI). Despite the inclusion of PEG/DSPE in liposomes, there was a significant drop in the plasma levels of DOX when the main phospholipid component, hydrogenated phosphatidylcholine, was replaced with lipids of lower phase transition temperature (dipalmitoylphosphatidylcholine, egg phosphatidylcholine), indicating that phase transition temperature affects the pharmacokinetics of liposome-encapsulated DOX. In beagle dogs, clearance was significantly slower for DOX encapsulated in PEG/ DSPE-containing liposomes than in HPI-containing liposomes, with distribution half-lives of 29 and 13 hr, respectively. In both instances, almost 100% of the drug measured in plasma was liposome-associated. The apparent volume of distribution was only slightly above the estimated plasma volume of the dogs, indicating that drug leakage from circulating liposomes is insignificant and that the distribution of liposomal drug is limited mostly to the intravascular compartment in healthy animals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. T. M. Allen and A. Chonn. Large unilamellar liposomes with low uptake by the reticuloendothelial system. FEBS Lett. 223:42–46 (1987).

    Google Scholar 

  2. A. Gabizon and D. Papahadjopoulos. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. USA 85:6949–6953 (1988).

    Google Scholar 

  3. T. M. Allen, C. Hansen, and J. Rutledge. Liposome with prolonged circulation times: Factors affecting uptake by reticuloendothelial system and other tissues. Biochim. Biophys. Acta 981:27–35 (1989).

    Google Scholar 

  4. A. L. Klibanov, K. Maruyama, V. P. Torchilin, and L. Huang. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 268:235–237 (1990).

    Google Scholar 

  5. G. Blume and G. Cevc. Liposomes for sustained drug release in vivo. Biochim. Biophys. Acta 1029:91–97 (1990).

    Google Scholar 

  6. J. Senior, C. Delgado, D. Fisher, C. Tilock, and G. Gregoriadis. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with polyethyleneglycol-coated vesicles. Biochim. Biophys. Acta 1062:77–82 (1991).

    Google Scholar 

  7. D. Papahadjopoulos, T. Allen, A. Gabizon, E. Mayhew, K. Matthay, S. K. Huang, K.-D. Lee, M. C. Woodle, D. D. Lasic, C. Redemann, and F. J. Martin. Sterically stabilized liposomes: Improvements in pharmacokinetics and anti-tumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88:11460–11464 (1991).

    Google Scholar 

  8. T. M. Allen, C. Hansen, F. Martin, C. Redemann, and A. Yau-Young. Liposomes containing synthetic lipid derivatives of polyethylene glycol show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066:29–36 (1991).

    Google Scholar 

  9. A. Gabizon and D. Papahadjopoulos. The role of surface charge and hydrophilic groups on liposome clearance in vivo. Biochim. Biophys. Acta 1103:94–100 (1992).

    Google Scholar 

  10. A. Gabizon, D. C. Price, J. Huberty, R. S. Bresalier, and D. Papahadjopoulos. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: Biodistribution and imaging studies. Cancer Res. 50:6371–6378 (1990).

    Google Scholar 

  11. A. Gabizon. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52:891–896 (1992).

    Google Scholar 

  12. A. Gabizon, R. Shiota, and D. Papahadjopoulos. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long-circulation times. J. Natl. Cancer Inst. 81:1484–1488 (1989).

    Google Scholar 

  13. G. Storm, L. Van Bloois, M. Brouwer, and D. J. Crommelin. The interaction of cytostatic drugs with adsorbents in aqueous media: The potential implications for liposome preparations. Biochim. Biophys. Acta 818:343–351 (1992).

    Google Scholar 

  14. S. Druckmann, A. Gabizon, and Y. Barenholz. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: Implications for pharmacokinetic studies. Biochim. Biophys. Acta 980:381–384 (1989).

    Google Scholar 

  15. P. A. Andrews, D. E. Brenner, F. E. Chou, H. Kubo, and N. R. Bachur. Facile and definitive determination of human adriamycin and daunorubicin metabolites by high-pressure liquid chromatography. Drug Metab. Disp. 8:152–156 (1980).

    Google Scholar 

  16. J. H. Beijnen, H. Rosing, P. A. De Vries, and W. J. Underberg. Stability of anthracycline antitumor agents in infusion fluids. J. Parent. Sci. Technol. 39:220–223 (1985).

    Google Scholar 

  17. S. Amselem, R. Cohen, S. Druckmann. A. Gabizon, D. Goren, R. M. Abra, A. Huang, R. New, and Y. Barenholz. Preparation and characterization of liposomal doxorubicin for human use. J. Liposome Res. 2:93–123 (1992).

    Google Scholar 

  18. S. Takanashi and N. R. Bachur. Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metab. Disp. 4:79–87 (1976).

    Google Scholar 

  19. A. Gabizon, R. Chisin, S. Amselem, S. Druckmann, R. Cohen, D. Goren, I. Fromer, T. Peretz, A. Sulkes, and Y. Barenholz. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. Br. J. Cancer 64:1125–1132 (1991).

    Google Scholar 

  20. M. Gibaldi and D. Perrier. Pharmacokinetics, Marcel Dekker, New York, 1982, pp. 445–449.

    Google Scholar 

  21. L. Z. Benet and R. L. Galazzi. Non-compartmental determination of steady state volume of distribution. J. Pharm. Sci. 68:1071–1074 (1979).

    Google Scholar 

  22. K. Yamaoka, T. Nakagawa, and T. Uno. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547–558 (1978).

    Google Scholar 

  23. K. Yamaoka. Methods for Pharmacokinetic Analysis for Personal Computers, Nanko-D Ltd., Tokyo, 1986, pp. 145–175.

    Google Scholar 

  24. R. F. Greene, J. M. Collins, J. F. Jenkins, J. L. Speyer, and C. E. Myers. Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res. 43:3417–3421 (1983).

    Google Scholar 

  25. J. H. Senior. Fate and behavior of liposomes in vivo: A review of controlling fators. CRC Crit. Rev. Ther. Drug Carrier Syst. 3:123–193 (1987).

    Google Scholar 

  26. R. K. Jain. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastas. Rev. 9:253–266 (1990).

    Google Scholar 

  27. M. C. Woodle and D. D. Lasic. Sterically stabilized liposomes. Biochim. Biophys. Acta 1113:171–199 (1992).

    Google Scholar 

  28. D. D. Lasic, F. J. Martin, A. Gabizon, S. K. Huang, and D. Papahadjopoulos. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times. Biochim. Biophys. Acta 1070:187–192 (1991).

    Google Scholar 

  29. A. Gabizon, R. Catane, B. Uziely, B. Kaufman, T. Safra, Y. Barenholz, and A. Huang. A pilot study of doxorubicin encapsulated in long-circulating (Stealth®) liposomes in cancer patients. Proc. Am. Soc. Clin. Oncol. 11:124 (1992).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sharett Institute of Oncology, Hadassah University Hospital, P.O.B. 12000, Jerusalem, 91120, Israel

    Alberto A. Gabizon

  2. Department of Membrane Biochemistry, Hebrew University–Hadassah School of Medicine, Jerusalem, Israel

    Yechezkel Barenholz

  3. Department of Pharmacy, School of Pharmacy, The Hebrew University of Jerusalem, P.O.B. 12065, Jerusalem, 91120, Israel

    Meir Bialer

Authors
  1. Alberto A. Gabizon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yechezkel Barenholz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Meir Bialer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gabizon, A.A., Barenholz, Y. & Bialer, M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharm Res 10, 703–708 (1993). https://doi.org/10.1023/A:1018907715905

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1018907715905

Search

Navigation